10-Q: Rallybio Reports Q2 2026 Results Amid Merger Activity

Rallybio Corporation filed its Form 10-Q for the quarter ended June 30, 2026, detailing financial results, ongoing merger plans with Avenzo Therapeutics, and operational updates.

Summary

• Rallybio Corporation reported its financial results for the quarter and six months ended June 30, 2026.
• The company received a $50.0 million termination fee from Candid Therapeutics, Inc. following the termination of their merger agreement.
• Rallybio entered into a merger agreement with Avenzo Therapeutics, Inc. on May 31, 2026, with Avenzo shareholders expected to own approximately 56.6% of the combined entity post-merger.
• Research and development expenses decreased significantly year-over-year, primarily due to the discontinuation of the RLYB212 program and reduced activity on RLYB116.
• General and administrative expenses increased due to merger-related legal and professional fees.
• The company ended the period with $92.8 million in cash and cash equivalents, which it believes is sufficient for at least 12 months.
• Rallybio continues to focus on its lead program, RLYB116, a C5 inhibitor for complement-related diseases, and RLYB332, a preclinical MTP-2 antibody for iron overload diseases.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic, primarily due to the significant termination fee received, which bolsters liquidity. However, the ongoing merger with Avenzo and the company's continued lack of product revenue present substantial future uncertainties.

Positives

• Received a $50.0 million termination fee from Candid Merger Agreement, significantly boosting cash reserves.
• Cash and cash equivalents increased to $92.8 million as of June 30, 2026, providing a runway of over 12 months.
• Significant reduction in R&D expenses compared to the prior year, reflecting strategic program adjustments.
• Completed confirmatory Phase 1 clinical trial for RLYB116, showing improved tolerability and sustained complement inhibition.

Negatives

• No product revenue generated, and the company continues to incur significant operating losses.
• The proposed merger with Avenzo Therapeutics introduces substantial integration and execution risks.
• Rallybio's existing stockholders are expected to own only approximately 2.8% of the combined company post-merger.
• The company's RLYB212 program was discontinued due to failure to achieve target concentrations.

Risks

• Failure to complete, or delays in completing, the proposed Merger with Avenzo could materially and adversely affect results of operations, business, financial results, and stock price.
• The company has incurred significant losses since inception and anticipates continued losses, requiring substantial additional capital.
• The success of RLYB116 is critical, and its early-stage development carries inherent risks of failure or significant delays.
• Enrollment and retention of patients in rare disease clinical trials is challenging and could lead to delays and increased costs.
• Marketing approval processes are lengthy, unpredictable, and may result in denial of approval.
• Competition from other biotechnology and pharmaceutical companies is significant.
• The company's ability to obtain and maintain patent protection for its technology and product candidates is crucial and uncertain.
• The company's limited resources and access to capital may necessitate prioritizing certain product candidates, potentially leading to adverse business outcomes.

Future Outlook

The company anticipates that its current cash and cash equivalents will be sufficient to fund its operating expenses and capital requirements for at least 12 months from the filing date, with the merger expected to close before the end of 2026. However, significant additional capital will be required to fund product candidates through regulatory approval and commercialization.

Management Comments

• We believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months beyond the filing of this Quarterly Report on Form 10-Q, although we anticipate that the Merger will close prior to the end of 2026.
• We have incurred significant operating losses since inception, including operating losses of $5.7 million and $10.1 million for the three months ended June 30, 2026 and 2025, respectively and $14.4 million and $19.7 million for the six months ended June 30, 2026 and 2025, respectively.
• The increase in total other income of $50.0 million was a result of the termination of the Candid Merger Agreement on May 4, 2026 and payment of the related termination fee.

Industry Context

StockSavvy.ai notes that Rallybio's situation is typical of many clinical-stage biotech companies, balancing the need for significant R&D investment with the pursuit of strategic transactions like mergers to advance pipeline assets or provide liquidity. The termination of one deal and the initiation of another with Avenzo highlights the dynamic nature of biotech M&A.

Comparison to Industry Standards

• Rallybio's R&D spending as a percentage of total operating expenses is high, which is common for clinical-stage biotechs, but the significant decrease in R&D spending in the current period compared to the prior year, driven by program discontinuation, is a notable shift.
• The company's cash burn rate, while still substantial, has been impacted by the termination fee, temporarily improving its liquidity position compared to companies solely reliant on ongoing operations.
• The pro forma ownership split post-merger (2.8% for Rallybio shareholders vs. 56.6% for Avenzo shareholders, excluding concurrent financing) is a critical factor for investors to consider, as it indicates a significant dilution for existing Rallybio shareholders.

Legal Proceedings

• No legal proceedings are currently disclosed that are expected to have a material adverse effect on the business.

Stakeholder Impact

• Rallybio shareholders face significant dilution, with expected ownership of only 2.8% of the combined company post-merger.
• The merger with Avenzo Therapeutics will result in Rallybio changing its name to Avenzo Therapeutics, Inc., impacting brand identity and stakeholder perception.
• Contingent Value Rights (CVRs) will be issued to holders of certain Rallybio securities, entitling them to a pro rata share of net proceeds from disposition agreements related to Rallybio's pre-merger assets and cash proceeds from Recursion.

Next Steps

• Complete the merger with Avenzo Therapeutics, Inc.
• Continue development of RLYB116, a C5 inhibitor.
• Advance RLYB332, a preclinical MTP-2 antibody, through development.
• Evaluate strategic alternatives following the termination of the Candid Merger Agreement.

Key Dates

Recommendation

The company's financial position has been significantly bolstered by the $50 million termination fee, providing a crucial liquidity runway. However, the ongoing merger with Avenzo Therapeutics, where Rallybio shareholders will hold a very small percentage of the combined entity, introduces significant execution risk and dilution. The lack of product revenue and continued operating losses mean that the company's future success is heavily reliant on the successful integration and future performance of the combined entity, making it a speculative investment. Therefore, a 'hold' recommendation is appropriate, pending further clarity on the merger's progress and the combined entity's strategic direction.

Keywords

Rallybio, Avenzo Therapeutics, Merger, RLYB116, Biotechnology, Clinical-stage, Form 10-Q, Complement inhibitor